← Leaderboards
Neal Rosen
Sloan-Kettering Institute For Cancer Res
$21,048,001
Attributed
$21,660,888
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2006–22$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$21,660,888 · 13
By mechanism
P01$7,612,897 · 4
R35$7,341,720 · 1
P50$4,306,602 · 6
U01$1,309,268 · 1
R01$1,090,401 · 1
Top collaborators
- Marc Ladanyi5 shared
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Pier Paolo Pandolfi$54,825,346
- Marc Ladanyi$28,443,479
- Glenn Heller$7,155,475
- William L Gerald$10,319,111
- Jason A Koutcher$20,695,436
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTumorMutationSignal PathwaySignal TransductionInhibitor/AntagonistPathway InteractionsPharmaceutical PreparationsMutantResistanceDoseCellsScheduleCombined Modality TherapyIn VivoFeedbackClinical TrialsGrowthNeoplastic CellMeksToxic EffectProto-Oncogene Proteins C-AktPten GeneOutput
Grant awards (57)
Studies on oncoprotein-induced feedback: Basic and therapeutic implications$1,056,048
R35 · FY2022 · CA · contact PI
Project 2: Targeting the ERK Pathway in KRAS- and BRAF-Driven Lung Cancers$284,558
P01 · FY2022 · CA · contact PI
Studies on oncoprotein-induced feedback: Basic and therapeutic implications$1,077,600
R35 · FY2021 · CA · contact PI
Project 2: Targeting the ERK Pathway in KRAS- and BRAF-Driven Lung Cancers$290,365
P01 · FY2021 · CA · contact PI
Research Project 2: Combined inhibition of AR and PI3K signaling in metastatic prostate cancer: Exploiting reciprocal feedback$113,342
P50 · FY2021 · CA · contact PI
Studies on oncoprotein-induced feedback: Basic and therapeutic implications$1,077,600
R35 · FY2020 · CA · contact PI
Project 2: Targeting the ERK Pathway in KRAS- and BRAF-Driven Lung Cancers$290,365
P01 · FY2020 · CA · contact PI
Research Project 2: Combined inhibition of AR and PI3K signaling in metastatic prostate cancer: Exploiting reciprocal feedback$170,181
P50 · FY2020 · CA · contact PI
Studies on oncoprotein-induced feedback: Basic and therapeutic implications$1,045,272
R35 · FY2019 · CA · contact PI
Project 2: Targeting the ERK Pathway in KRAS- and BRAF-Driven Lung Cancers$278,073
P01 · FY2019 · CA · contact PI
Research Project 2: Combined inhibition of AR and PI3K signaling in metastatic prostate cancer: Exploiting reciprocal feedback$170,468
P50 · FY2019 · CA · contact PI
Studies on oncoprotein-induced feedback: Basic and therapeutic implications$1,028,400
R35 · FY2018 · CA · contact PI
Development of Mechanism-based Strategies for the Treatment of AdvancedBreast C$544,711
P01 · FY2018 · CA · contact PI
Project 2: Targeting the ERK Pathway in KRAS- and BRAF-Driven Lung Cancers$286,672
P01 · FY2018 · CA · contact PI
Research Project 2: Combined inhibition of AR and PI3K signaling in metastatic prostate cancer: Exploiting reciprocal feedback$179,441
P50 · FY2018 · CA · contact PI
Studies on oncoprotein-induced feedback: Basic and therapeutic implications$1,028,400
R35 · FY2017 · CA · contact PI
Development of Mechanism-based Strategies for the Treatment of AdvancedBreast C$543,981
P01 · FY2017 · CA · contact PI
Research Project 2: Combined inhibition of AR and PI3K signaling in metastatic prostate cancer: Exploiting reciprocal feedback$179,756
P50 · FY2017 · CA · contact PI
Studies on oncoprotein-induced feedback: Basic and therapeutic implications$1,028,400
R35 · FY2016 · CA · contact PI
Development of Mechanism-based Strategies for the Treatment of AdvancedBreast C$548,363
P01 · FY2016 · CA · contact PI
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$248,430
P01 · FY2016 · CA · contact PI
Research Project 2: Combined inhibition of AR and PI3K signaling in metastatic prostate cancer: Exploiting reciprocal feedback$171,770
P50 · FY2016 · CA · contact PI
Development of Mechanism-based Strategies for the Treatment of AdvancedBreast C$548,728
P01 · FY2015 · CA · contact PI
Developing therapeutic strategies for ERK-dependent tumors$368,728
R01 · FY2015 · CA · contact PI
Clinical Development of Next-Generation Antiandrogens and the Impact of PTEN Status$249,619
P50 · FY2015 · CA · contact PI
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$248,430
P01 · FY2015 · CA · contact PI
Development of Mechanism-based Strategies for the Treatment of AdvancedBreast C$545,765
P01 · FY2014 · CA · contact PI
Developing therapeutic strategies for ERK-dependent tumors$357,666
R01 · FY2014 · CA · contact PI
Clinical Development of Next-Generation Antiandrogens and the Impact of PTEN Status$247,311
P50 · FY2014 · CA · contact PI
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$240,985
P01 · FY2014 · CA · contact PI
Developing therapeutic strategies for ERK-dependent tumors$364,007
R01 · FY2013 · CA · contact PI
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C$250,448
P50 · FY2013 · CA · contact PI
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$233,526
P01 · FY2013 · CA · contact PI
Development of Mechanism-Based Strategies for the Treatment of Advanced Breast Ca$443,410
P01 · FY2012 · CA · contact PI
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C$263,815
P50 · FY2012 · CA · contact PI
Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers$254,404
P01 · FY2012 · CA · contact PI
Development of Mechanism-Based Strategies for the Treatment of Advanced Breast Ca$442,882
P01 · FY2011 · CA · contact PI
Development of Mechanism-Based Strategies for the Treatment of Advanced Breast Ca$456,578
P01 · FY2010 · CA · contact PI
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C$361,919
P50 · FY2010 · CA · contact PI
Development of Methodologies for the In Vivo Imaging og the Effects of Novel Inhi$223,770
P50 · FY2010 · CA · contact PI
Development of Mechanism-Based Strategies for the Treatment of Advanced Breast Ca$447,626
P01 · FY2009 · CA · contact PI
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C$362,472
P50 · FY2009 · CA · contact PI
Development of Methodologies for the In Vivo Imaging og the Effects of Novel Inhi$223,770
P50 · FY2009 · CA · contact PI
Development of Mechanism-Based Strategies for the Treatment of Advanced Breast Ca$435,045
P01 · FY2008 · CA · contact PI
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C$418,592
P50 · FY2008 · CA · contact PI
Development of Methodologies for the In Vivo Imaging og the Effects of Novel Inhi$122,547
P50 · FY2008 · CA · contact PI
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C$413,330
P50 · FY2007 · CA · contact PI
HSP90 AS A TARGET FOR MECHANISM-BASED THERAPY FOR CASTRATION-RESISTANT PROSTATE C$184,051
P50 · FY2006 · CA · contact PI
Hsp90s as targets in the development of anticancer drugs$320,580
U01 · FY2004 · CA
Hsp90s as targets in the development of anticancer drugs$296,732
U01 · FY2003 · CA
Hsp90s as targets in the development of anticancer drugs$332,176
U01 · FY2002 · CA
Effects of ansamycin antibiotics on breast cancers$0
P01 · FY2002 · CA
Imaging the in vivo anti-tumor effects of ansamycins$0
P50 · FY2002 · CA
Imaging the in vivo anti-tumor effects of ansamycins$0
P50 · FY2002 · CA
Hsp90s as targets in the development of anticancer drugs$359,780
U01 · FY2001 · CA
Imaging the in vivo anti-tumor effects of ansamycins$0
P50 · FY2001 · CA
Imaging the in vivo anti-tumor effects of ansamycins$0
P50 · FY2000 · CA